Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +17.95%
#2 clBTC clBTC +12.17%
#3 Wrapped Ether (Mantle Bridge) Wrapped Ether (Mantle Bridge) +8.67%
#4 Mantle Staked Ether Mantle Staked Ether +8.27%
#5 Palladium Network Palladium Network +6.69%
#6 Not in Employment, Education, or Training Not in Employment, Education, or Training +6.66%
#7 OpenEden OpenEden +6.37%
#8 EfficientFrontier EfficientFrontier +5.09%
#9 Momentum Momentum +4.55%
#10 Nockchain Nockchain +3.90%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Synairgen plc Synairgen plc

Synairgen plc

SNG
Kedudukan dalam Saham #40400
Synairgen plc specializes in the research and development of pharmaceutical... Synairgen plc specializes in the research and development of pharmaceutical treatments for various respiratory conditions. Its product pipeline includes SNG001, an inhaled interferon beta currently being developed for COVID-19. The company is also advancing an inhaled form of interferon beta (IFN-ß) through Phase II clinical trials for the management of asthma triggered by common colds and influenza, as well as for the treatment or prevention of chronic obstructive pulmonary disease. Furthermore, Synairgen is developing a LOXL2 inhibitor intended for treating idiopathic pulmonary fibrosis (IPF). To support the development of this LOXL2 inhibitor, the company maintains a licensing and collaboration agreement with Pharmaxis Ltd. Synairgen plc was established in 2004 and is headquartered in Southampton, United Kingdom.
Harga Saham
$0.01292666
Disegerakkan terakhir: 2025-04-08
Modal Pasaran
$157.54K
Perubahan (1 hari)
6.84%
Perubahan (1 tahun)
0.00%
Negara
GB
Perdagangan Synairgen plc (SNG)

Kategori

Healthcare
Pendapatan untuk Synairgen plc (SNG)
Pendapatan pada Jun 2024 TTM: $-4.64M
Menurut laporan kewangan terkini Synairgen plc, pendapatan semasa syarikat ialah $-4.64M. Pada tahun 2022, syarikat memperoleh pendapatan sebanyak $-24.31M, peningkatan berbanding pendapatan pada tahun 2021 yang berjumlah $-78.22M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Synairgen plc dari 2004 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
2026 (TTM) $-4.64M -62.26%
2023 $-12.29M -49.43%
2022 $-24.31M -68.92%
2021 $-78.22M 222.66%
2020 $-24.24M 281.43%
2019 $-6.36M 121,729.64%
2018 $-5.22K -336.99%
2017 $2.20K -100.05%
2016 $-4.20M 111,307.18%
2015 $-3.77K -315.15%
2014 $1.75K -100.05%
2013 $-3.75M -6.03%
2012 $-4.00M -32.03%
2011 $-5.88M 34.57%
2010 $-4.37M -6.90%
2009 $-4.69M -4.50%
2008 $-4.91M 29.79%
2007 $-3.78M 57.39%
2006 $-2.40M 119.97%
2005 $-1.09M 293.81%
2004 $-277.59K 0.00%
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -113,800.85%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -42,146.41%
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -64,888.45%
BE